PAS
HRTX icon

PKS Advisory Services’s Heron Therapeutics HRTX Stock Holding History

PKS Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.54K Hold
20,000
– – ﹤0.01% 379
2026
Q1 		$16K Buy
+20,000
New +$23.2K ﹤0.01% 228
2025
Q4 		– Sell
-20,000
Closed -$25.2K – 261
2025
Q3 		$25.2K Buy
+20,000
New +$31.7K 0.01% 244

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

PKS Advisory Services's HRTX Position: Q2 2026 in Review

PKS Advisory Services held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 20,000 shares worth $8.54K. The position accounts for ﹤0.01% of the portfolio, ranked #379.

PKS Advisory Services first reported a position in HRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $25.2K in Q3 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • PKS Advisory Services held 20,000 shares of Heron Therapeutics worth $8.54K as of Q2 2026.
  • PKS Advisory Services left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of PKS Advisory Services's portfolio in Q2 2026, its #379 holding.
  • PKS Advisory Services first reported a position in Heron Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PKS Advisory Services's Heron Therapeutics position peaked at $25.2K in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on PKS Advisory Services's 13F filing for Q2 2026, filed 4 Aug 2026.